Work

Identification and characterization of a novel agonistic anti-DR4 human monoclonal antibody

Year: 2010

Type: article

Abstract: The tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been established as promising targets for cancer treatment. Therapeutics targeting TRAIL and its receptors are not only effective in killing many types of tumors, but they also synergize with traditional therapies and show efficacy against tumors that are otherwise resistant to conventional treatments. We describe here the identification and characterization of two human monoclonal antibodies, m921 and m922, that are specific for human DR4. Both antibodies competed with TRAIL for binding to DR4, but only m921 recognized cell surface-associated DR4 and inhibited the growth of ST486 cells. This antibody may have potential for further development as a candidate therapeutic and research tool.

Source: mAbs

DOI: 10.4161/mabs.2.5.12570

Authors: Yang Feng, Xiaodong Xiao, Zhongyu Zhu, Dimiter S. Dimitrov

Institutions: National Institutes of Health, Frederick National Laboratory for Cancer Research, National Cancer Institute

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,575